Stockscreener 앱 받기
29.07
3.84%
1.075
Arrowhead Pharmaceuticals Inc 주식(ARWR)의 최신 뉴스
Arrowhead Pharmaceuticals and Novartis sign global deal for siRNA therapy - MSN
Arrowhead Pharmaceuticals Inc. stock outlook for YEARPortfolio Performance Report & Long Hold Capital Preservation Plans - Newser
Arrowhead Pharmaceuticals Inc. stock trendline breakdownMarket Activity Summary & Weekly High Return Stock Forecasts - Newser
Should value investors consider Arrowhead Pharmaceuticals Inc.Share Buyback & Weekly Top Gainers Alerts - خودرو بانک
Is Arrowhead Pharmaceuticals Inc. stock risky to hold now2025 Year in Review & High Accuracy Investment Signals - خودرو بانک
News impact scoring models applied to Arrowhead Pharmaceuticals Inc.July 2025 Catalysts & Free Safe Entry Trade Signal Reports - Newser
Can Arrowhead Pharmaceuticals Inc. grow without dilutionMarket Movers & Weekly Stock Performance Updates - خودرو بانک
Can Arrowhead Pharmaceuticals Inc. be recession proof2025 Historical Comparison & Safe Entry Momentum Tips - خودرو بانک
Smart tools for monitoring Arrowhead Pharmaceuticals Inc.’s price action2025 Risk Factors & Consistent Growth Equity Picks - Newser
Arrowhead Pharmaceuticals at Cantor Global Healthcare Conference - AInvest
Transcript : Arrowhead Pharmaceuticals, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-04-2025 09 - MarketScreener
What is Arrowhead Pharmaceuticals Inc. s 5 year growth outlookTrade Signal Summary & Free Real-Time Volume Trigger Notifications - خودرو بانک
What’s next for Arrowhead Pharmaceuticals Inc. stock priceQuarterly Trade Review & Breakout Confirmation Trade Signals - Newser
Arrowhead Pharmaceuticals Shares Drop After Sarepta Sells Stake - MSN
Arrowhead Pharmaceuticals shares rise 3.82% intraday after insider sold shares. - AInvest
Identifying reversal signals in Arrowhead Pharmaceuticals Inc.2025 Fundamental Recap & Low Risk Growth Stock Ideas - Newser
Jim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn’t Make Any Money” - MSN
Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal - Mitrade
Will earnings trigger a reversal in Arrowhead Pharmaceuticals Inc.July 2025 Retail & Verified Momentum Watchlists - Newser
Using Python tools to backtest Arrowhead Pharmaceuticals Inc. strategiesPortfolio Risk Report & Real-Time Volume Spike Alerts - Newser
How to forecast Arrowhead Pharmaceuticals Inc. trends using time seriesQuarterly Market Review & Fast Gain Stock Trading Tips - Newser
Will Arrowhead Pharmaceuticals Inc. benefit from AI trendsJuly 2025 Big Picture & Real-Time Buy Signal Notifications - خودرو بانک
Will breakout in Arrowhead Pharmaceuticals Inc. lead to full recoveryWatch List & Real-Time Market Sentiment Reports - Newser
Will Arrowhead Pharmaceuticals Inc. announce a stock splitWeekly Trend Report & AI Enhanced Trading Signals - خودرو بانک
Arrowhead Pharmaceuticals Inc (ARWR) Insider Sell: James Hamilto - GuruFocus
Analyzing recovery setups for Arrowhead Pharmaceuticals Inc. investorsJuly 2025 Macro Moves & Daily Growth Stock Investment Tips - Newser
Analyzing net buyer seller activity in Arrowhead Pharmaceuticals Inc. - Newser
Arrowhead Pharmaceuticals' Chief Medical Officer Sells 15,000 Shares at $25/Share - AInvest
Arrowhead Pharmaceuticals at Cantor Global Healthcare: Strategic Moves and Market Positioning - Investing.com
Can a trend reversal in Arrowhead Pharmaceuticals Inc. lead to recoveryPortfolio Update Summary & Verified High Yield Trade Plans - Newser
Is Arrowhead Pharmaceuticals Inc. stock entering bullish territoryWeekly Investment Recap & Entry Point Confirmation Signals - Newser
Using data models to predict Arrowhead Pharmaceuticals Inc. stock movementShare Buyback & AI Enhanced Market Trend Forecasts - Newser
Arrowhead Lands Billion-Dollar Biotech Deal: Stock Soars Double-Digits - Yahoo Finance
Arrowhead Pharmaceuticals at Citi’s Biopharma Conference: Strategic Insights - Investing.com
Transcript : Arrowhead Pharmaceuticals, Inc. Presents at Citi's Biopharma Back to School Conference, Sep-03-2025 01 - MarketScreener
Arrowhead: Upcoming Plozasiran PDUFA Review Date And Subsequent Expansion In Place (ARWR) - Seeking Alpha
Arrowhead Pharmaceuticals stock hits 52-week high at 27.35 USD - Investing.com
Tick level data insight on Arrowhead Pharmaceuticals Inc. volatilityJuly 2025 Gainers & Real-Time Buy Zone Alerts - Newser
Arrowhead and Novartis sign agreement for ARO-SNCA - BioWorld MedTech
Arrowhead Pharma stock gets Buy rating reaffirmed by H.C. Wainwright - Investing.com
Arrowhead Pharmaceuticals Inc.’s volatility index tracking explainedPortfolio Profit Report & AI Forecast for Swing Trade Picks - Newser
Arrowhead Pharmaceuticals Inc. stock momentum explained2025 Performance Recap & Technical Entry and Exit Alerts - Newser
Detecting price anomalies in Arrowhead Pharmaceuticals Inc. with AI2025 Fundamental Recap & High Accuracy Swing Trade Signals - Newser
Arrowhead Pharmaceuticals shares fall 1.40% premarket after announcing a global licensing and collaboration agreement with Novartis for ARO-SNCA. - AInvest
Using Ichimoku Cloud for Arrowhead Pharmaceuticals Inc. technicalsPortfolio Return Summary & Low Drawdown Momentum Ideas - Newser
Arrowhead Pharmaceuticals Inc. stock volume spike explainedJuly 2025 Retail & Daily Chart Pattern Signals - Newser
Arrowhead hits the skids due to partnership with Sarepta - MSN
Stocks To Watch: Arrowhead Pharm Sees RS Rating Jump To 89 - Investor's Business Daily
1.40%
자본화:
|
볼륨(24시간):